William Blair & Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.4M | Sell |
81,152
-21,715
| -21% | -$2.71M | 0.03% | 344 |
|
|
2025
Q4 | $12.5M | Buy |
102,867
+1,057
| +1% | +$121K | 0.03% | 316 |
|
|
2025
Q3 | $10.2M | Buy |
101,810
+2,590
| +3% | +$233K | 0.03% | 354 |
|
|
2025
Q2 | $8.23M | Sell |
99,220
-38,301
| -28% | -$3.06M | 0.02% | 388 |
|
|
2025
Q1 | $11.2M | Sell |
137,521
-2,233
| -2% | -$200K | 0.03% | 311 |
|
|
2024
Q4 | $12.6M | Sell |
139,754
-4,112
| -3% | -$398K | 0.04% | 308 |
|
|
2024
Q3 | $14.2M | Buy |
143,866
+2,351
| +2% | +$231K | 0.04% | 292 |
|
|
2024
Q2 | $13.1M | Sell |
141,515
-9,047
| -6% | -$811K | 0.04% | 290 |
|
|
2024
Q1 | $14.3M | Buy |
150,562
+45,053
| +43% | +$4.18M | 0.04% | 272 |
|
|
2023
Q4 | $9.42M | Sell |
105,509
-2,159
| -2% | -$160K | 0.03% | 333 |
|
|
2023
Q3 | $7.86M | Sell |
107,668
-1,492
| -1% | -$119K | 0.03% | 347 |
|
|
2023
Q2 | $9.08M | Buy |
109,160
+2,048
| +2% | +$171K | 0.03% | 327 |
|
|
2023
Q1 | $8.16M | Sell |
107,112
-402
| -0.4% | -$33.4K | 0.03% | 345 |
|
|
2022
Q4 | $8.92M | Buy |
107,514
+4,570
| +4% | +$370K | 0.04% | 312 |
|
|
2022
Q3 | $8.17M | Buy |
102,944
+31,285
| +44% | +$2.64M | 0.04% | 318 |
|
|
2022
Q2 | $5.32M | Buy |
71,659
+15,041
| +27% | +$1.13M | 0.02% | 405 |
|
|
2022
Q1 | $5.09M | Sell |
56,618
-21,809
| -28% | -$2.01M | 0.02% | 463 |
|
|
2021
Q4 | $8.78M | Sell |
78,427
-12,762
| -14% | -$1.54M | 0.03% | 366 |
|
|
2021
Q3 | $11.5M | Buy |
91,189
+4,639
| +5% | +$597K | 0.04% | 306 |
|
|
2021
Q2 | $11.7M | Sell |
86,550
-7,605
| -8% | -$1,000K | 0.04% | 299 |
|
|
2021
Q1 | $12.8M | Sell |
94,155
-157,590
| -63% | -$23.6M | 0.05% | 278 |
|
|
2020
Q4 | $35.4M | Buy |
251,745
+198,640
| +374% | +$25.4M | 0.13% | 158 |
|
|
2020
Q3 | $5.92M | Buy |
53,105
+29,983
| +130% | +$3.36M | 0.03% | 362 |
|
|
2020
Q2 | $2.59M | Buy |
23,122
+12,246
| +113% | +$1.21M | 0.01% | 501 |
|
|
2020
Q1 | $842K | Sell |
10,876
-708
| -6% | -$62.7K | 0.01% | 718 |
|
|
2019
Q4 | $1.1M | Sell |
11,584
-3,373
| -23% | -$292K | 0.01% | 755 |
|
|
2019
Q3 | $1.14M | Sell |
14,957
-2,726
| -15% | -$227K | 0.01% | 710 |
|
|
2019
Q2 | $1.55M | Sell |
17,683
-16,925
| -49% | -$1.44M | 0.01% | 648 |
|
|
2019
Q1 | $3.13M | Buy |
34,608
+26,046
| +304% | +$2.22M | 0.02% | 449 |
|
|
2018
Q4 | $614K | Buy |
8,562
+3,779
| +79% | +$304K | ﹤0.01% | 839 |
|
|
2018
Q3 | $459K | Buy |
4,783
+388
| +9% | +$37.6K | ﹤0.01% | 984 |
|
|
2018
Q2 | $418K | Buy |
4,395
+1,215
| +38% | +$112K | ﹤0.01% | 1003 |
|
|
2018
Q1 | $279K | Buy |
3,180
+402
| +14% | +$36.7K | ﹤0.01% | 1094 |
|
|
2017
Q4 | $236K | Buy |
+2,778
| New | +$233K | ﹤0.01% | 1218 |
|
|
2017
Q3 | – | Sell |
-2,936
| Closed | -$227K | – | 1526 |
|
|
2017
Q2 | $227K | Buy |
+2,936
| New | +$208K | ﹤0.01% | 1293 |
|
|
2017
Q1 | – | Sell |
-6,508
| Closed | -$385K | – | 1515 |
|
|
2016
Q4 | $385K | Buy |
+6,508
| New | +$402K | ﹤0.01% | 920 |
|
Other funds holding XBI
William Blair & Company's XBI Position: Q1 2026 in Review
William Blair & Company reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 21% in Q1 2026, selling an estimated $2.71M and leaving 81,152 shares worth $10.4M. The position accounts for 0.03% of the portfolio, ranked #344.
William Blair & Company first reported a position in XBI in Q4 2016 and has held it in 36 quarters since. The position peaked at $35.4M in Q4 2020. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- William Blair & Company held 81,152 shares of State Street SPDR S&P Biotech ETF worth $10.4M as of Q1 2026.
- William Blair & Company sold 21,715 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $2.71M.
- State Street SPDR S&P Biotech ETF made up 0.03% of William Blair & Company's portfolio in Q1 2026, its #344 holding.
- William Blair & Company first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 36 quarters since.
- William Blair & Company's State Street SPDR S&P Biotech ETF position peaked at $35.4M in Q4 2020.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.